Clinical Bulletin - Losartan Drug Recall - Coventry
Clinical Bulletin
November 27, 2018
Subject: Voluntary Recall of Medications Containing Losartan
Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg, indicated for the treatment of hypertension.1
Recall Details
This recall is due to a trace amount of impurity N-nitrosodiethylamine (NDEA) being detected in one lot of Losartan Potassium Hydrochlorothiazide Tablets, which was distributed nationwide beginning October 8, 2018. Details regarding the recalled lot can be found on the U.S. Food & Drug Administration (FDA) Drug Recall website. The FDA recommends patients taking the recalled lot to follow the instructions provided by Sandoz on their website.
For additional recall information, visit:
The Impact
Currently, First Script shows no impact to injured workers due to this recall.
For more information, please contact your Account Manager or Account Pharmacist.
1.
The foregoing information provides a summary overview of certain statutory and/or regulatory provisions. This summary is not comprehensive and does not constitute legal advice. It is for informational purposes only and should be independently verified by client's legal counsel. Review of the full text of referenced statutes and regulations may be necessary.
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- blood pressure drug recall 2019
- fda drug recall list 2018
- blood pressure drug recall list
- drug recall list 2018
- drug recall list
- fda drug recall list
- losartan on recall 2019 torrent brand
- 2019 losartan lot recall list
- losartan potassium recall 2019
- fda losartan potassium recall 2019
- losartan hctz recall 2019
- losartan hydrochlorothiazide recall 2019